Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris

详细信息	查看全文 | 推荐本文 |

• 作者：Mercedes Kuroski de Bold^a ; ^{mdebold@ottawaheart.ca} ; William P. Sheffield^b ; Amy Martinuk^a ; Varsha Bhakta^b ; Louise Eltringham-Smith^b ; Adolfo J. de Bold^a
• 关键词：ANF ; atrial natriuretic factor ; EH ; essential hypertension ; CHF ; congestive heart failure ; AMI ; acute myocardial infarction ; BP ; blood pressure ; HSA ; human serum albumin ; cGMP ; cyclic guanosine mono-phosphatase ; iv ; intravenous ; HSA-ANF ; human serum album
• 刊名：Regulatory Peptides
• 出版年：2012
• 期刊代码：68_01670115
• 类别：neu
• 出版时间：10 April, 2012
• 卷：175
• 期：1-3
• 页码：7-10
• 文件大小：545 K

摘要

The cardiac hormone atrial natriuretic factor (ANF) combines pharmacological properties of drugs used to treat essential hypertension (EH), congestive heart failure (CHF) and acute myocardial infarction (AMI). Treatment of CHF or AMI patients with an intravenous (iv) infusion of the circulating form of ANF (ANF_99-126) produces significant clinical improvement. The short half-life (5 min) and peptide nature of ANF impose logistic restrictions for chronic administration. To increase its half-life, we fused ANF and human serum albumin (HSA) mini-genes by recombination in Pichia pastoris. The activity of three configurations of the fusion protein was tested in vitro and in vivo. The fusion protein that comprised of C-terminus HSA connected to N-terminus ANF via a hexaglycine linker showed the best outcome; it increased cGMP production in vitro. In vivo an iv bolus of HSA-ANF into mice increased significantly plasma cGMP levels and lowered blood pressure (BP) for up to 6 h hence successfully extended ANF half-life in plasma while retaining its biological activity. HSA-ANF represents the basis for development in the chronic therapeutic use of ANF.